Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc.
03:49pm, Wednesday, 09'th Dec 2020
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. (ZYNE)
The Law Offices of Frank R. Cruz Announces Investigation of Zynerba Pharmaceuticals (ZYNE) on Behalf of Investors
12:00pm, Monday, 07'th Dec 2020
LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or the
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
11:30am, Friday, 04'th Dec 2020
- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 -
DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n
11 Cannabis Stocks Making Moves While Riding the 'Green Wave'
02:29pm, Friday, 13'th Nov 2020
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
06:45am, Monday, 09'th Nov 2020
DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n
Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
04:04am, Thursday, 29'th Oct 2020
Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meeting is exp
